Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
Background. Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefore, we assessed the effectiveness and safety of gra...
Main Authors: | Ute Eisenberger, MD, Justa Friebus-Kardash, MD, Hana Guberina, MD, Andreas Kribben, MD, Oliver Witzke, MD, Katharina Willuweit, MD, Guido Gerken, MD, Kerstin Herzer, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2019-01-01
|
Series: | Transplantation Direct |
Online Access: | http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000860 |
Similar Items
-
Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
by: Steven Flamm MD, et al.
Published: (2019-01-01) -
Grazoprevir/elbasvir combination therapy for HCV infection
by: Anaïs Vallet-Pichard, et al.
Published: (2017-01-01) -
Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
by: Meghan E. Sise, et al.
Published: (2020-04-01) -
Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
by: Zhdanov K, et al.
Published: (2020-04-01) -
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
by: Jin Chen, et al.
Published: (2020-01-01)